<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56960">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364557</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-BR002</org_study_id>
    <secondary_id>NCI-2014-01810</secondary_id>
    <secondary_id>NRG-BR002</secondary_id>
    <secondary_id>NRG-BR002</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <nct_id>NCT02364557</nct_id>
  </id_info>
  <brief_title>Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer</brief_title>
  <official_title>A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial studies how well standard of care therapy with
      stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy
      alone in treating patients with breast cancer that has spread to one or two locations in the
      body (limited metastatic) that are previously untreated. Standard of care therapy comprising
      chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of
      tumor cells. Radiation therapy and/or surgery is usually only given with standard of care
      therapy to relieve pain; however, in patients with limited metastatic breast cancer,
      stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to
      send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be
      able to effectively remove the metastatic tumor cells. It is not yet known whether standard
      of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating
      limited metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether ablation (through stereotactic body radiation therapy [SBRT]
      [stereotactic radiosurgery] and/or surgical resection of all known metastases) in
      oligometastatic breast cancer patients provides a sufficient signal for improved
      progression-free survival (PFS) to warrant full accrual to the Phase III portion of the
      trial. (Phase II-R) II. To determine whether ablation (through SBRT and/or surgical
      resection of all known metastases) in oligometastatic breast cancer patients significantly
      improves overall survival (OS). (Phase III)

      SECONDARY OBJECTIVES:

      I. To evaluate treated metastasis control according to tumor receptor status (estrogen
      receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor [HER]-2),
      use of chemotherapy, surgery vs. ablative therapy, and solitary metastasis vs. 2 metastasis
      (may expand to &gt;= 2 to =&lt; 4 following completion of a Phase I trial).

      II. To evaluate whether the addition of ablative metastasis directed therapy significantly
      reduces the number of distant recurrences (new metastases) in patients who progress
      according to tumor receptor status (ER, PR, HER-2); use of chemotherapy, and solitary
      metastasis vs. 2 metastases (may expand to &gt;= 2 to =&lt; 4 following completion of the Phase I
      NRG-BR001 trial).

      III. To evaluate adverse events in patients who receive ablative metastasis-directed therapy
      to all known metastases in addition to standard medical therapy alone.

      IV. To explore the most appropriate and clinically relevant technological parameters to
      ensure quality and effectiveness throughout the radiation therapy processes, including
      imaging, simulation, target and critical structure definition, treatment planning, image
      guidance, and delivery.

      TERTIARY OBJECTIVES:

      I. To determine whether &lt; 5 circulating tumor cells (CTCs) (per 7.5 ml of blood) is an
      independent prognostic (outcome) marker for improved PFS and OS in oligometastatic breast
      cancer.

      II. To determine whether &lt; 5 CTCs (per 7.5 ml of blood) is an independent predictive
      (response to therapy) marker for improved PFS and OS in oligometastatic breast cancer.

      III. To determine whether eliminating CTCs (0/7.5 ml of blood in patients with at least 2
      CTCs at registration) is both a prognostic and predictive marker for improved PFS and OS.

      IV. To evaluate the prognostic and predictive properties of CTC count as a continuous
      measure of PFS and OS.

      V. To store material for retrospective analysis of circulating tumor deoxyribonucleic acid
      (ctDNA).

      VI. To store material for retrospective analysis of circulating micro-ribonucleic acid
      (RNA).

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM 1: Patients continue to receive their current planned systemic therapy at the discretion
      of the treating physician.

      ARM 2: Patients continue to receive their current planned systemic therapy at the discretion
      of the treating physician. Patients also undergo stereotactic radiosurgery in 1, 3, or 5
      fractions within 3 weeks and/or surgery at the discretion of the treating physician.

      ARM 1: Patients are followed every 3 months from randomization to 2 years. ARM 2: Patients
      are followed 25-35 days post-ablation, every 3 months from randomization to 2 years, and
      then yearly thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (failure: progression or death due to any cause) (Phase II-R)</measure>
    <time_frame>From the date of randomization to the date of first PFS failure or last follow-up; assessed up to 3 years</time_frame>
    <description>Progression-free survival will be estimated by the Kaplan-Meier method, with progression defined as: progression of initial/treated metastases (using the revised Response Evaluation Criteria in Solid Tumors [RECIST] guideline), appearance of new metastases, or death due to any cause. The distribution of PFS estimates between the two arms will be compared using the log rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (failure: death due to any cause) (Phase III)</measure>
    <time_frame>From the date of randomization to the date of death or last follow-up; assessed up to 8 years</time_frame>
    <description>Overall survival will be estimated by the Kaplan-Meier method. The distribution of OS estimates between the two arms will be compared using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appearance of new metastases</measure>
    <time_frame>From the date of randomization to the date of the first appearance of any new metastases; assessed up to 8 years</time_frame>
    <description>Failure for this endpoint will be the appearance of any new metastases. The cumulative probability of new metastases in the presence of competing failure events will be estimated by the cumulative incidence method. The cumulative incidence distributions between the two arms will be compared using Gray's test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with the incidence of new metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded according to National Cancer Institute CTCAE version 4</measure>
    <time_frame>From the date of randomization to the date of death or last follow-up; assessed up to 2 years</time_frame>
    <description>The frequencies and severity of adverse events by treatment arm will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial presence of CTCs in blood samples</measure>
    <time_frame>Baseline</time_frame>
    <description>The prognostic effect of the initial presence of CTCs at baseline on PFS (OS) will be evaluated using the Cox proportional hazards model, controlling for treatment effect and stratification factors. The hypothesis tests will be two-sided and will use an alpha level of 0.05 to determine significance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of CTCs after treatment in blood samples</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The interaction between treatment effect and the initial presence of CTCs at baseline on PFS (OS) will be evaluated in the Cox model, which will include an indicator for treatment group, an indicator for presence of CTCs (&gt;= 5 per 7.5 ml of blood), and their interaction term. The analysis will be adjusted for the stratification factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CTC count in blood samples</measure>
    <time_frame>Baseline to up to 3 months</time_frame>
    <description>The effect of change in CTC count from CTC &gt;= 2 per 7.5 ml of blood at baseline to CTC = 0 at follow-up after initial treatment on PFS (OS) will be evaluated using the Cox proportional hazards model, controlling for treatment effect and stratification factors. The analyses will be conditional on a patient's event-free survival up to post-treatment evaluation. The interaction between treatment effect and change in CTC count will be evaluated in the Cox model, which will include an indicator for treatment group, an indicator for change of CTCs, and their interaction term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of ctDNA in plasma samples</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The prognostic effect of dichotomized ctDNA on PFS (OS) will be evaluated using the Cox proportional hazards model, controlling for treatment effect and stratification factors. In addition, the presence of the interaction between treatment effect and dichotomized ctDNA will be evaluated (predictive effect). Spearman rank correlation coefficient will be used to correlate the levels of CTCs and ctDNA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Dyspnea</condition>
  <condition>Fatigue</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Pain</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (standard of care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients continue to receive their current planned systemic therapy at the discretion of the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (stereotactic radiosurgery, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients continue to receive their current planned systemic therapy at the discretion of the treating physician. Patients also undergo stereotactic radiosurgery in 1, 3, or 5 fractions within 3 weeks and/or surgery at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Undergo stereotactic radiosurgery</description>
    <arm_group_label>Arm 2 (stereotactic radiosurgery, surgery)</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>Stereotactic External Beam Irradiation</other_name>
    <other_name>Stereotactic Radiation Therapy</other_name>
    <other_name>Stereotactic Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm 2 (stereotactic radiosurgery, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm 2 (stereotactic radiosurgery, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed metastatic breast cancer within 270 days prior to
             registration

          -  Known estrogen, progesterone, and HER2 status of either primary tumor or metastasis

          -  =&lt; 2 metastases seen on standard imaging within 30 days prior to registration

          -  Controlled primary tumor site defined as &gt;= 3 months (90 days) recurrence-free
             interval since completion of definitive surgical management

          -  All known disease amenable to metastasis-directed therapy with either SBRT or
             resection

               -  NOTE: Symptomatic bone metastasis are allowed if ablative therapy can be
                  delivered

               -  NOTE: Sites for possible surgical excision include lung, liver, adrenal gland,
                  bone, small intestine, large intestine, ovary, and amenable nodal disease sites

               -  NOTE: Surgical stabilization is allowed for a metastasis if it is followed by
                  conventionally fractionated external beam radiotherapy

          -  Maximum diameter of individual metastasis in any dimension =&lt; 5 cm

          -  Metastases must be &gt; 5 cm away from each other (defined as Edge to Edge of tumor)

               -  NOTE: If metastases are =&lt; 5 cm away from each other, consider enrollment in
                  NRG-BR001

          -  First-line standard systemic therapy (chemotherapy, anti-endocrine therapy, anti-HER2
             or other standard targeted therapy) for metastatic breast cancer not to have exceeded
             a duration of 6 months at the time of registration

          -  Appropriate stage for study entry based on the following diagnostic workup:

               -  History/physical examination within 30 days prior to registration

               -  Computed tomography (CT) scans of the chest, abdomen, and pelvis with
                  radionuclide bone scan OR whole body positron emission tomography (PET)/CT
                  within 30 days prior to study registration

          -  Zubrod performance status =&lt; 2 within 30 days prior to registration

          -  Absolute neutrophil count (ANC) &gt;= 500 cells/mm^3

          -  Platelets &gt;= 50,000 cells/mm^3

          -  Hemoglobin &gt;= 8.0 g/dl (note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] &gt;= 8.0 g/dl is acceptable)

          -  For females of child-bearing potential, negative serum or urine pregnancy test within
             14 days prior to study registration

          -  The patient must provide study-specific informed consent prior to study entry

        Exclusion Criteria:

          -  Pathologic evidence of local/regional breast tumor recurrence

          -  Co-existing or prior invasive malignancy (except non-melanomatous skin cancer),
             unless disease free for a minimum of 3 years

          -  Metastases with indistinct borders making targeting not feasible

               -  NOTE: A potential issue with bone metastases is that they often are not
                  discrete; since many patients on this protocol will have bone metastases, this
                  will be an important issue; theoretically, Houndsfield units might provide an
                  appropriate measure; however, a sclerotic lesion against dense cortical bone
                  will not have a sharp demarcation based on Houndsfield units (HU); therefore, we
                  acknowledge that such determinations will pose a challenge and thus the
                  physician's judgment will be required

          -  Prior palliative radiation treatment for metastatic disease

          -  Metastases located within 3 cm of the previously irradiated structures:

               -  Spinal cord previously irradiated to &gt; 40 Gy

               -  Brachial plexus previously irradiated to &gt; 50 Gy

               -  Small intestine, large intestine, or stomach previously irradiated to &gt; 45 Gy

               -  Brainstem previously irradiated to &gt; 50 Gy

               -  Lung previously irradiated with prior V20Gy &gt; 30%

          -  Brain metastases

          -  Exudative, bloody, or cytological proven malignant effusions

          -  Severe, active co-morbidity defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of
                  registration

          -  Pregnancy; lactating females must cease expression of milk prior to signing consent
             to be eligible

          -  Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4
             count &lt; 200 cells/microliter; note that patients who are HIV positive are eligible,
             provided they are under treatment with highly active antiretroviral therapy (HAART)
             and have a CD4 count &gt;= 200 cells/microliter within 30 days prior to registration;
             note also that HIV testing is not required for eligibility for this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Chmura</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer F. De Los Santos</last_name>
      <phone>205-978-3928</phone>
      <email>jdelossantos@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer F. De Los Santos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James J. Urbanic</last_name>
      <phone>858-822-5354</phone>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>James J. Urbanic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parima Daroui</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Parima Daroui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Permanente Medical Group-Roseville Radiation Oncology</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Cancer Treatment Center</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel A. Rabinovitch</last_name>
      <phone>720-848-0234</phone>
      <email>rachel.rabinovitch@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Rachel A. Rabinovitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel A. Rabinovitch</last_name>
      <phone>720-848-0234</phone>
      <email>rachel.rabinovitch@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Rachel A. Rabinovitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinath Sundararaman</last_name>
      <phone>954-983-3471</phone>
      <email>ssundararaman@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Srinath Sundararaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinath Sundararaman</last_name>
      <phone>954-983-3471</phone>
      <email>ssundararaman@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Srinath Sundararaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon T. Kahn</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Shannon T. Kahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam W. Nowlan</last_name>
      <phone>404-425-7943</phone>
      <email>ORS@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Adam W. Nowlan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon T. Kahn</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Shannon T. Kahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon T. Kahn</last_name>
      <phone>404-778-4369</phone>
      <email>shannon.kahn@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Shannon T. Kahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan B. Strauss</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan B. Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine L. Griem</last_name>
      <phone>312-563-2857</phone>
      <email>clinical_trials@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine L. Griem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy F. Chen</last_name>
      <phone>312-355-3046</phone>
    </contact>
    <investigator>
      <last_name>Lucy F. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhishek A. Solanki</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Abhishek A. Solanki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Warrenville</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy M. Kesslering</last_name>
      <phone>630-315-1918</phone>
      <email>Claudine.Gamster@CadenceHealth.org</email>
    </contact>
    <investigator>
      <last_name>Christy M. Kesslering</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Anderson Regional Hospital/Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander M. Yeh</last_name>
      <phone>765-646-8358</phone>
    </contact>
    <investigator>
      <last_name>Alexander M. Yeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital Randallia</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian K. Chang</last_name>
      <phone>260-373-8888</phone>
      <email>parkviewresearch@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Brian K. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A. Hornback</last_name>
      <phone>800-284-7370</phone>
    </contact>
    <investigator>
      <last_name>David A. Hornback</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaker R. Dakhil</last_name>
      <phone>316-262-0706</phone>
      <email>shaker.dakhil@cancercenterofkansas.com</email>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Feigenberg</last_name>
      <phone>410-328-5279</phone>
      <email>sfeigenberg@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Steven J. Feigenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upper Chesapeake Medical Center</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark V. Mishra</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Mark V. Mishra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea B. McKee</last_name>
      <phone>603-663-1800</phone>
    </contact>
    <investigator>
      <last_name>Andrea B. McKee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Y. Chen</last_name>
      <phone>248-551-0089</phone>
      <email>peter.chen@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Peter Y. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Zoberi</last_name>
      <phone>800-600-3606</phone>
      <email>info@ccadmin.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Imran Zoberi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew O. Wahl</last_name>
      <phone>402-559-6941</phone>
      <email>unmcrsa@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew O. Wahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley A. Jarvis</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Lesley A. Jarvis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Memorial</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>609-914-6762</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>609-914-6762</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Gan</last_name>
      <phone>505-925-0274</phone>
      <email>ggan@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana L. Fox</last_name>
      <phone>718-231-5064</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Jana L. Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph K. Salama</last_name>
      <phone>888-275-3853</phone>
      <email>joseph.salama@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph K. Salama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice A. Lyons</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Janice A. Lyons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose G. Bazan</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jose G. Bazan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence S. Herman</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence S. Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NRG Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Chmura</last_name>
      <phone>773-702-0817</phone>
      <email>schmura@radonc.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Steven J. Chmura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence P. Cescon</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Terrence P. Cescon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven W. Corso</last_name>
      <phone>864-560-1055</phone>
      <email>scorso@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Steven W. Corso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
      <email>vivek.kavadi@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy A. Woodward</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Wendy A. Woodward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher N. Watson</last_name>
      <phone>304-598-4717</phone>
      <email>sfilburn@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher N. Watson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin D. Driscoll</last_name>
      <phone>608-775-2385</phone>
      <email>cancerctr@gundersenhealth.org</email>
    </contact>
    <investigator>
      <last_name>Collin D. Driscoll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry M. Muanza</last_name>
      <phone>514-934-4400</phone>
      <email>tmuanza@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Thierry M. Muanza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry M. Muanza</last_name>
      <phone>514-934-4400</phone>
      <email>tmuanza@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Thierry M. Muanza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 17, 2016</lastchanged_date>
  <firstreceived_date>February 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
